Profile 7: Multiple Sclerosis (MS)
In multiple sclerosis, FMT is investigational: it targets immune balance and gut symptoms but never replaces disease-modifying therapy and must be guided alongside your neurologist.
| Parameter | MS-specific detail |
|---|---|
| Evidence level | ★★☆☆☆ Early-stage. Observational data consistently show MS-associated gut dysbiosis; animal EAE models demonstrate microbiota-mediated immune modulation. Small case series and pilot trials in humans show tolerability and preliminary signals of benefit. No large RCTs completed. FMT for MS is investigational. |
| Mechanism of dysbiosis | Reduced regulatory T-cell-inducing commensals (Clostridia clusters IV and XIVa, Bacteroides fragilis polysaccharide A producers). Elevated Akkermansia in some MS subtypes (paradoxically associated with increased intestinal permeability in this context). Dysbiosis amplifies Th17/Treg imbalance, driving CNS autoimmunity. Intestinal permeability increases systemic microbial antigen exposure, potentially cross-reacting with myelin epitopes. |
| Primary microbiota targets | Restore Clostridia clusters IV and XIVa (Treg-inducing). Normalise intestinal permeability (tight junction support). Reduce pro-inflammatory Th17-inducing taxa. Support SCFA production for peripheral immune calibration. Modulate bile acid pool affecting nuclear receptor signaling relevant to myelination. |
| Protocol modification | Full 4-phase protocol. Immunomodulatory medications (interferons, natalizumab, ocrelizumab, etc.) — consult treating neurologist before FMT: some DMTs may impair engraftment by reducing immune integration of donor microbiota; others may be synergistic. Relapsing-remitting MS: avoid FMT initiation during active relapse. Progressive MS: longer maintenance protocols under evaluation. |
| Minimum transfer duration | 90 days minimum. Neuroimmunological outcomes require sustained microbiota-immune co-regulation. Preliminary protocols suggest 6–12-month maintenance phases for immune stabilisation. |
| Priority exposome focus | Vitamin D optimisation (critical in MS; VDR-microbiota interactions directly relevant). High-fiber, anti-inflammatory diet (Mediterranean or similar). Avoid smoking (independently worsens MS and dysbiosis). Stress management (psychological stress triggers both MS relapses and dysbiosis). Physical activity adapted to disability level — directly improves microbiota diversity. |
| Expected response timeline | Intestinal permeability markers: 6–12 weeks. Inflammatory biomarkers: 3–6 months. MS relapse frequency: not established as primary endpoint; requires long-term follow-up and neurological assessment. Fatigue (a key MS symptom): may improve within 8–12 weeks via gut-brain axis modulation. |
| Warning signs (MS-specific) | Any new neurological symptoms or worsening of existing deficits after FMT initiation — immediate neurological assessment required. Fever (potential pseudo-relapse trigger in MS — Uhthoff phenomenon). Urinary tract infections (common in MS, dysbiosis-mediated, may worsen after microbiota disruption before stabilisation). Severe fatigue worsening (distinguish from expected post-FMT adaptation vs. inflammatory relapse). |
Table 18 – Clinical profile: Multiple Sclerosis (MS) # Protocol parameters, evidence level, and clinical modifications specific to MS.
Note: FMT in MS is investigational. All treatment decisions must be made in conjunction with the patient's neurologist and MS care team. Disease-modifying therapies should not be interrupted without neurological guidance.
Engen et al. 2024 (Annals of Neurology) systematic review identifies three consistent MS-microbiota patterns: reduced Prevotella, reduced butyrate producers, reduced tryptophan-AhR[G] signaling activity [438]. Phase 2 FMT trials (small n) showed preliminary EDSS improvement. A phase 3 pivotal trial is awaited; clinical application remains experimental.
MS-FMT Clinical Considerations (2024)
- Indication window: relapsing-remitting MS (RRMS), on DMT, exacerbation-free for 6 months — preliminary evidence is most robust in this subgroup.
- Delivery route: capsule FMT with 8-week consolidation; intensive colonoscopic delivery is not recommended during active inflammation.
- Expected clinical signal: improvement in concomitant GI symptoms (constipation in ~40% of MS patients) is the primary short-term endpoint; EDSS stabilization is the long-term endpoint.
- Mechanistic framework: AhR-mediated immune modulation by indole derivatives[G] and the kynurenine pathway[G] reduces CNS inflammation.
Patients must be informed: MS-FMT is available exclusively under clinical trial protocols and does not replace DMT therapy (interferon, glatiramer, dimethyl fumarate, sphingosine-1-phosphate modulators).
References
[438] Engen, P. A., Zaferiou, A., Rasmussen, H., et al. Gastrointestinal microbiome alterations in multiple sclerosis. Annals of Neurology. 2020. Link
The authors characterized gut-microbiome alterations in multiple sclerosis, highlighting reduced short-chain-fatty-acid (butyrate) producers and Prevotella, together with altered tryptophan metabolism / AhR signalling as consistent MS-associated dysbiosis patterns. These changes align with immune dysregulation (Th17/Treg imbalance) and the gut-brain axis in MS.